Cogent Biosciences plans to submit a drug application to the FDA for bezuclastinib, which was studied using TSS.
1 report, 0 independent
Updated Jul 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cogent Biosciences plans to submit a drug application to the FDA for bezuclastinib, which was studied using TSS.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Cogent Biosciences (United States)
company in Waltham, United States
Nothing else this week.
-
TSS
Czech company
Nothing else this week.
Related events
- Cogent Biosciences plans to submit an NDA to the FDA, with Andrew Robbins as President and CEO.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- The FDA recommended advancement for a new drug application submitted by a company.
Coverage
Newest first; wire copies grouped- Unknown outlet